SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

9 Apr 2013 07:00

RNS Number : 8085B
Victrex PLC
09 April 2013
 



Victrex plc

 

Half Year Trading Update

 

The Company announces its trading update for the six months ended 31 March 2013.

 

Trading

We are pleased to report that, despite continued global economic challenges, Group sales volume for the first half of 1,392 tonnes was ahead of the same period for last year (1,377 tonnes). As expected, this reflects a stronger performance from our Victrex Polymer Solutions business ('VPS') in the second quarter with Group sales volume of 752 tonnes compared to the first quarter of 640 tonnes. The first half has also seen continued progress from speciality products, predominantly driven by success in our Aptiv® films business.

 

In our Invibio® Biomaterial Solutions business ('Invibio') the de-stocking we reported at selected spine customers in the second half of last year has continued resulting in revenues for the first half of £24.2m compared to £25.5m for the same period last year. We have made further progress with regulatory approvals in the spine market in Asia and the initial response to the launch of our dental product line, JUVORATM, has been positive.

 

Management appointment

We are pleased to report the appointment of Dr Martin Court as Managing Director of our Invibio business. Prior to joining Victrex, Martin was Vice President of In Process Separation at Cytec Industries Inc. Martin brings a wealth of experience to the management team having held senior strategic, international, general management and technical roles within Cytec, UCB and ICI.

 

Outlook

We remain vigilant of the challenges that persist in some of our end markets, however the initial order book for April is robust.

 

The opportunities to drive growth into new markets, applications and geographies remain strong. We continue to work with customers and end users on focused application development and our key growth programmes to ensure the potential for our business is realised.

 

Our capital investment programme remains on track, including our Victrex PEEK capacity expansion as well as projects to further develop our capability in downstream processing such as film, pipes and composites.

 

 

Victrex will host a conference call at 9.00am today for analysts. If you would like more details, please contact Rosa Smith at MHPC on 0203 128 8560 / Rosa.Smith@mhpc.com.

 

Victrex will announce its results for the six months ended 31 March 2013 on Tuesday 28 May 2013.

 

Enquiries

 

Victrex plc

Steve Barrow, Finance Director 0203 128 8100 (9 April 2013)

01253 897700 (thereafter)

 

MHP Communications

Nick Denton / Barnaby Fry / Ian Payne 0203 128 8100

 

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK polymer, a high performance, easy to process thermoplastic.

 

With over 30 years of experience, Victrex is a provider of innovative, high performance thermoplastic polymers. We work with customers and end users globally to deliver technology driven solutions to the challenges and opportunities they face. Our Victrex Polymer Solutions business unit ('VPS') focuses on our transport, industrial and electronics markets and our Invibio® Biomaterial Solutions business unit ('Invibio') focuses on providing specialist solutions for medical device manufacturers.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGUWCCUPWGGR
Date   Source Headline
11th Oct 20194:18 pmRNSHolding(s) in Company
8th Oct 20193:09 pmRNSHolding(s) in Company
7th Oct 20194:06 pmRNSHolding(s) in Company
3rd Oct 20194:18 pmRNSHolding(s) in Company
30th Sep 201911:53 amRNSTotal Voting Rights
18th Sep 20199:19 amRNSDirector/PDMR Shareholding
30th Aug 20199:00 amRNSTotal Voting Rights
19th Aug 201911:44 amRNSDirector/PDMR Shareholding
14th Aug 201910:39 amRNSHolding(s) in Company
31st Jul 20199:01 amRNSTotal Voting Rights
25th Jul 20197:00 amRNSInterim Management Statement
17th Jul 201910:38 amRNSDirector/PDMR Shareholding
28th Jun 20199:00 amRNSTotal Voting Rights
24th Jun 20197:00 amRNSDirectorate Change
18th Jun 201910:42 amRNSDirector/PDMR Shareholding
3rd Jun 20191:55 pmRNSBlock listing Interim Review
31st May 20193:12 pmRNSDirector/PDMR Shareholding
31st May 20199:00 amRNSTotal Voting Rights
20th May 201910:09 amRNSDirector/PDMR Shareholding
17th May 201910:50 amRNSDirector/PDMR Shareholding
15th May 20198:49 amRNSDirector/PDMR Shareholding
13th May 20197:00 amRNSHalf-year Report
30th Apr 201910:00 amRNSTotal Voting Rights
17th Apr 201912:03 pmRNSDirector/PDMR Shareholding
29th Mar 201912:07 pmRNSTotal Voting Rights
19th Mar 201910:55 amRNSDirector/PDMR Shareholding
28th Feb 20199:33 amRNSTotal Voting Rights
19th Feb 201910:42 amRNSDirector/PDMR Shareholding
18th Feb 20194:23 pmRNSDirector/PDMR Shareholding
11th Feb 20194:34 pmRNSHolding(s) in Company
8th Feb 20199:44 amRNSHolding(s) in Company
6th Feb 20192:28 pmRNSResult of AGM
6th Feb 20191:55 pmRNSDirector/PDMR Shareholding
6th Feb 20197:00 amRNSAGM and Q1 Interim Management Statement
4th Feb 201912:18 pmRNSDirector/PDMR Shareholding
31st Jan 20199:29 amRNSTotal Voting Rights
28th Jan 20194:28 pmRNSHolding(s) in Company
17th Jan 201911:21 amRNSDirector/PDMR Shareholding
11th Jan 20193:44 pmRNSHolding(s) in Company
3rd Jan 20191:00 pmRNSAnnual Financial Report
31st Dec 20189:00 amRNSTotal Voting Rights
18th Dec 20183:19 pmRNSDirector/PDMR Shareholding
18th Dec 201810:30 amRNSDirector/PDMR Shareholding
17th Dec 201811:40 amRNSDirector/PDMR Shareholding
11th Dec 20189:50 amRNSDirector/PDMR Shareholding
11th Dec 20189:48 amRNSDirector/PDMR Shareholding
5th Dec 20181:47 pmRNSDirector/PDMR Shareholding
5th Dec 201812:35 pmRNSDirector/PDMR Shareholding
4th Dec 20187:00 amRNSPreliminary Results 2018
3rd Dec 20189:25 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.